Nascent Biotech & Manhattan BioSolutions Participate In a Panel Discussion On The TB Vaccine Development For COVID-19
SAN DIEGO, CA / ACCESSWIRE / August 4, 2020 / Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled “BCG: a therapeutic modality for COVID-19 and cancers” hosted by the Bioidea Group (https://bioidea.co/2020/07/13/bcg-covid-19/). The virtual session featured distinguished clinicians and scientists working on the TB / BCG vaccine for COVID-19 and cancer. The event was moderated by Dr. Navpaul Singh, Chief Medical Consultant from Nascent Biotech, Inc and live-streamed to social media platforms. Live stream recording is available on YouTube: https://www.youtube.com/watch?v=SumCzJOn0nc.
San Diego, CA, August 4, 2020-Nascent Biotech, Inc (OTCQB:NBIO), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat cancers and viral infections, has participated in the recent expert panel discussion entitled “BCG: a therapeutic modality for COVID-19 and cancers” hosted by the Bioidea Group (https://bioidea.co/2020/07/13/bcg-covid-19/). The virtual session featured distinguished clinicians and scientists working on the TB / BCG vaccine for COVID-19 and cancer. The event was moderated by Dr. Navpaul Singh, Chief Medical Consultant from Nascent Biotech, Inc and live-streamed to social media platforms. Live stream recording is available on YouTube: https://www.youtube.com/watch?v=SumCzJOn0nc.
Manhattan BioSolutions, Inc. founder and CEO, Dr. Boris Shor, who also participated in the discussion, highlighted the recent collaboration agreement with Nascent Biotech and ongoing objectives between the two companies. Dr. Shor reasserted that Manhattan BioSolutions is focused on the discovery of the next-generation therapies for the treatment of cancer and inflammatory diseases and that its unique oncology programs could also be applied towards the discovery of novel agents against COVID-19 to significantly impact the current and future viral outbreaks. The two companies signed the research agreement in May of this year and have since initiated a vaccine program for the potential prevention of COVID-19 or other viral infections. This effort will augment Nascent’s current development plans to investigate the utility of its monoclonal antibody Pritumumab for the treatment of COVID-19, as announced earlier in March.
Dr. Boris Shor reiterated, “Manhattan BioSolutions has a longstanding commitment to advance the basic research of immunotherapies, and we are excited to be working with Nascent Biotech on constructing a vaccine to prevent COVID-19 around the world. The latest literature revealed a correlation showing that countries with higher rates of Bacille Calmette-Guérin (BCG) vaccinations had lower peak mortality rates from COVID-19. These beneficial effects of BCG (TB vaccine) against viral infections are proposed to be mediated by the stimulation of innate immune mechanisms, also termed trained immunity. Clinical trials around the world are underway to investigate the protective effects of BCG against COVID-19. Our novel platform will be based on the recombinant BCG, genetically engineered to express selected SARS-CoV-2 proteins. The new design addresses major limitation of old-generation unmodified BCG to stimulate the human immune system broadly: a lack of specificity to SARS- CoV-2. Together, we will be in a strong position to advance the discovery and development of an innovative vaccination platform against coronaviruses.”
About Nascent Biotech
Nascent Biotech, Inc. (OTCQB:NBIO) is a clinical-stage biotech company pioneering the development of monoclonal antibodies (mAbs) for the treatment of incurable cancers such as brain and pancreas, as well as hard-to-treat cancers such as colon and lung. Nascent is also employing its mAbs as part of treatments for dangerous viral infections, such as COVID-19. Collectively, cancers and viral infections afflict and kill tens of millions worldwide each year. Nascent’s products are not commercially available. Our lead candidate, Pritumumab (PTB), is a fully-human mAb that will commence study in an FDA-approved Phase I clinical trial later this year for the treatment of primary and metastatic brain cancer, including glioblastoma and malignant astrocytoma. Development of PTB as a potential treatment for COVID-19 has been initiated. For more information, visit www.nascenbiotech.com.
About Manhattan BioSolutions
Manhattan BioSolutions, Inc is a privately held biotechnology company focused on the discovery and development of immunotherapies that target innate immunity for the treatment of cancer and inflammatory diseases. Manhattan BioSolutions leverages two technology platforms for drug discovery: a microbial-based genetically engineered immune stimulator platform, and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous “danger signals” released as a result of tissue injury or inflammation.
Statements in this press release about our future expectations constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, Nascent Biotech Inc’s ability to target the medical professionals, Nascent Biotech Inc’s ability to raise capital, as well as other risks. Additional information about these and other factors may be described in the Nascent Biotech Inc’s Form 10, filed on May 2, 2015, and future subsequent filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
President | CEO
Nascent Biotech, Inc.
6330 Nancy Ridge Dr
San Diego CA 92121
Boris Shor, PhD